Patrick Yat

Dr. Patrick N. Yat is currently V.P. Chemistry and Analytical Services at IntelliPharmaCeutics Corp.  He has been in the pharmaceutical or pharmaceutical related industry since 1992.  Dr. Yat’s Ph.D. research on Opioid analgesics was supported by the pharmaceutical industry.

As a Visiting Research Scientist under NSERC, Dr. Yat worked in the Pharmaceutical Division of Heath Canada, where he was involved in client methods validation under DIN submissions as well as in methods development and validation for inclusion in pharmacopoeia.   Dr. Yat’s one-year term at Health Canada was further extended to the maximum two years, which saw him carrying out synthesis of enalapril metabolites and developing HPLC chiral methods for that compound.

As the core scientist involved in the development of HPLC methods for nutriceuticals for the American Botanical Council, Dr. Yat, while at the University of Ottawa, was in charge of methods development and analysis for ginseng products sold in the North American market.   The ginseng methodology from this contribution is now part of the current U.S. Pharmacopoeia.  Dr. Yat held the title of Research Associate at the University of Ottawa, and stood in at times to offer specialized lectures on phytochemistry to graduate students.

Dr. Yat was also at Biovail Corporation in the mid 90’s, where he was involved in methods development and validation of the company’s pipeline products, as well as in heading the preformulation activity of the company. At Patheon Inc. in the late 90’s, he was instrumental in the successful take off of the Preformulation unit.

Dr. Yat joined the IntelliPharmaCeutics team in 2001. There, he continued to build the in-house analytical testing methods which are applied to all products developed at the Company. He has also overseen the general development of the Analytical department to its present status as a fully GMP compliant testing laboratory.

Dr. Yat currently sits as an expert committee member of the United States Pharmacopoeia on methods development, and is also on the advisory board of the Toronto Institute of Pharmaceutical Technology in its Quality Control program.